leadf
logo-loader
viewAlbion Capital Group

Albion Capital backs UK startup automating clinical trial processes

The company is already delivering its technology to the University of Oxford’s RAPTOR study evaluating the use of different COVID-19 rapid diagnostic tools in different community settings

Albion Capital Group -

Albion Capital Group has contributed to a £3.7mln fundraising round carried out by health tech startup uMed with UK and Silicon Valley investors.

The platform built by uMed automates the processes used in clinical trials, creating regulatory-quality patient registries that combine electronic health data with structured data captured from each patient.

READ: Albion VCTs invest in UK machine learning startup Seldon

By automating the process, it is designed to allow healthcare providers of all sizes, from small GP practices to large hospitals, to participate in multiple research programmes simultaneously without increasing overhead or burdens for drug developers.

Currently, uMed is already delivering its technology to a number of clinical research studies, including the University of Oxford’s RAPTOR study evaluating the use of different COVID-19 rapid diagnostic tools in different community settings, such as GP surgeries.

The uMed platform provides the functionality required to digitally target and engage patients for this study, Albion said, automatically and remotely collating the outcomes of the tests and linking the results back to the data from each patient record, which is said creates the capacity for healthcare providers to participate in many more of these studies than would otherwise be possible.  

AlbionVC, the investment manager’s technology investment arm, has been impressed by the potential power of this platform for the life sciences sector.

Christoph Ruedig, partner at AlbionVC, said: “uMed has developed a powerful platform that can link some of the richest sources of healthcare data and drive a step change in how clinical and real-world research is conducted. We have been impressed by the company and its vision, and we are excited to support them as they enter the next stage of growth.”

Alongside AlbionVC, others that participated in the funding round included existing backer Playfair Capital, Delin Ventures and Silicon Valley-based 11.2 Capital.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Albion Capital Group named herein, including the promotion by the Company of Albion Capital Group in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Albion Capital offer investors 'good, regular, steady income stream'

Albion Capital's (LON:AAVC) Will Fraser-Allen talks to Proactive London about their long term investment strategy, with assets totalling just under £450m worth of VTCs. The fund focuses on health and technology as well as some additional assets that they have built up historically which...

on 14/12/20

2 min read